Questions about this study?
The HopeStage team will email you.
TerminatedNCT00965419
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
Researchers are studying Edivoxetine, tracking side effects to assess long-term safety and tolerability in children with ADHD.
Medication studyAges 6–18Multiple countries
Understand this study
What is this study about?
Researchers are studying Edivoxetine, tracking side effects to assess long-term safety and tolerability in children with ADHD.
Who could participate?
This study is for people with ADHD. Listed age limits: 6 years to 18 years. Other eligibility criteria apply.
- Listed locations
- Spring Valley, United States · Gainesville, United States and 17 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateSeptember 2009
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 267
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States, Canada, Taiwan
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT00965419
- Official title
Show the full official title
Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder
Recruitment & locations
TerminatedSpring Valley, United States · Gainesville, United States · Orlando, United States
16 more locations
- University Park, United States
- Smyrna, United States
- Libertyville, United States
- Indianapolis, United States
- Rochester Hills, United States
- Omaha, United States
- Las Vegas, United States
- Philadelphia, United States
- Memphis, United States
- Lake Jackson, United States
- Lubbock, United States
- Herndon, United States
- Seattle, United States
- Kelowna, Canada
- Santurce, Puerto Rico
- Kuei Shan Hsiang, Taiwan
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are studying Edivoxetine, tracking side effects to assess long-term safety and tolerability in children with ADHD.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Does this study involve medication?
Yes. The study involves medication, including Edivoxetine.
Who can participate?
This study is for people with ADHD. Listed age limits: 6 years to 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder